Molecular Partners Valuation

Is MOLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOLN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOLN's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOLN?

Other financial metrics that can be useful for relative valuation.

MOLN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does MOLN's PS Ratio compare to its peers?

The above table shows the PS ratio for MOLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.5x
SANN Santhera Pharmaceuticals Holding
1.6x27.3%CHF85.8m
BSLN Basilea Pharmaceutica
3x8.7%CHF478.9m
KURN Kuros Biosciences
7.3xn/aCHF245.8m
IDIA Idorsia
1.9x24.2%CHF359.8m
MOLN Molecular Partners
15.9x43.8%CHF111.8m

Price-To-Sales vs Peers: MOLN is expensive based on its Price-To-Sales Ratio (15.9x) compared to the peer average (3.5x).


Price to Earnings Ratio vs Industry

How does MOLN's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: MOLN is expensive based on its Price-To-Sales Ratio (15.9x) compared to the European Biotechs industry average (9.8x).


Price to Sales Ratio vs Fair Ratio

What is MOLN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOLN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15.9x
Fair PS Ratio0.005x

Price-To-Sales vs Fair Ratio: MOLN is expensive based on its Price-To-Sales Ratio (15.9x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF3.40
CHF9.35
+175.0%
60.4%CHF15.00CHF3.70n/a2
Apr ’25CHF3.68
CHF9.50
+158.5%
57.9%CHF15.00CHF4.00n/a2
Mar ’25CHF3.82
CHF9.50
+148.7%
57.9%CHF15.00CHF4.00n/a2
Feb ’25CHF4.14
CHF9.50
+129.5%
57.9%CHF15.00CHF4.00n/a2
Jan ’25CHF3.44
CHF9.50
+176.2%
57.9%CHF15.00CHF4.00n/a2
Dec ’24CHF3.87
CHF10.50
+171.7%
42.9%CHF15.00CHF6.00n/a2
Nov ’24CHF3.19
CHF10.50
+229.7%
42.9%CHF15.00CHF6.00n/a2
Oct ’24CHF3.86
CHF10.50
+172.4%
42.9%CHF15.00CHF6.00n/a2
Sep ’24CHF5.14
CHF9.00
+75.1%
47.1%CHF15.00CHF6.00n/a3
Aug ’24CHF5.49
CHF9.00
+63.9%
47.1%CHF15.00CHF6.00n/a3
Jul ’24CHF5.42
CHF9.00
+66.1%
47.1%CHF15.00CHF6.00n/a3
Jun ’24CHF5.51
CHF14.00
+154.1%
80.8%CHF30.00CHF6.00n/a3
May ’24CHF5.97
CHF13.00
+117.8%
76.5%CHF30.00CHF6.00CHF3.294
Apr ’24CHF5.43
CHF12.87
+137.0%
69.2%CHF30.00CHF6.00CHF3.685
Mar ’24CHF6.01
CHF12.87
+114.1%
69.2%CHF30.00CHF6.00CHF3.825
Feb ’24CHF5.85
CHF12.87
+120.0%
69.2%CHF30.00CHF6.00CHF4.145
Jan ’24CHF6.16
CHF12.87
+108.9%
69.2%CHF30.00CHF6.00CHF3.445
Dec ’23CHF6.83
CHF12.87
+88.4%
69.2%CHF30.00CHF6.00CHF3.875
Nov ’23CHF6.46
CHF12.87
+99.2%
69.2%CHF30.00CHF6.00CHF3.195
Oct ’23CHF6.55
CHF19.39
+196.0%
74.8%CHF50.00CHF6.00CHF3.866
Sep ’23CHF5.36
CHF21.47
+300.6%
66.3%CHF50.00CHF6.00CHF5.146
Aug ’23CHF6.09
CHF26.47
+334.7%
55.1%CHF50.00CHF6.00CHF5.496
Jul ’23CHF6.59
CHF26.81
+306.8%
52.7%CHF50.00CHF8.00CHF5.426
Jun ’23CHF7.09
CHF26.81
+278.1%
52.7%CHF50.00CHF8.00CHF5.516
May ’23CHF7.89
CHF26.83
+240.1%
47.4%CHF50.00CHF10.00CHF5.977

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.